Tofacitinib Reduces KL-6 Levels in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease. Results Of A Phase II Investigator-Initiated Study.

Study limitation reported by the research below: “KL-6 units appear inconsistently reported in the abstract (mU/mL at baseline, mU/L for the decline) — this likely reflects a transcription error in the source text.”